Vizgen October 2024 Series D Funding Round

Vizgen, a leading spatial transcriptomics company, has announced a merger with Ultivue, a specialist in multiplex proteomic spatial tissue profiling. Alongside the merger, Vizgen has completed its Series D financing round, although the amount raised remains undisclosed. Key investors include Arch Venture Partners, Northpond Ventures, and Tao Capital Partners. Rob Carson, former CEO of Ultivue, will assume the role of CEO and president of the combined company. This merger aims to advance spatial multiomics by integrating Vizgen's genomic technology with Ultivue's proteomic expertise, driving innovation in discovery and clinical development.